Quebec to impose health tax on unvaccinated Canadians

12 January 2022 - The Canadian province of Quebec will charge a health tax to residents who are not vaccinated ...

Read more →

Valeo Pharma obtains public reimbursement for Enerzair Breezhaler and Atectura Breezhaler in Quebec and Nova Scotia

15 December 2021 - Public reimbursement now includes Alberta, Quebec and Nova Scotia, representing approximately 37% of the Canadian population. ...

Read more →

Lilly Canada concludes successful negotiation with the Pan-Canadian Pharmaceutical Alliance for Baqsimi (glucagon nasal powder)

30 November 2021 - Lilly Canada is pleased to announce the completion of a successful negotiation with the pan-Canadian Pharmaceutical Alliance ...

Read more →

What happened to the promise of universal pharmacare?

25 November 2021 - Canada is the only developed country in the world with a universal health care system that ...

Read more →

It’s time to better support the three million Canadians with a rare disease

25 November 2021 - After finding out her private health insurer would no longer pay for a drug helping with ...

Read more →

Valeo Pharma obtains public reimbursement for Enerzair Breezhaler and Atectura Breezhaler in Alberta

3 November 2021 - First provincial public listing secured for both asthma medications. ...

Read more →

Alnylam receives positive reimbursement recommendation from the CADTH for use of Givlaari for the treatment of acute hepatic porphyria in adults

18 October 2021 - Givlaari reduces chronic pain, improves quality of life and is the first and only therapy proven ...

Read more →

Novartis applauds Quebec, the first province to list Zolgensma for the treatment of paediatric patients with spinal muscular atrophy

15 October 2021 - Public reimbursement under the Régie de l'assurance maladie du Québec, effective October 20th will apply for children ...

Read more →

Novartis and the pan-Canadian Pharmaceutical Alliance complete negotiations for Zolgensma for the treatment of paediatric patients with spinal muscular atrophy

13 October 2021 - Novartis Pharmaceuticals Canada today announced that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance for a ...

Read more →

Outdated criteria for drug plan reimbursement obstruct evidence based care

12 October 2021 - An important flaw in the funding approach used by Canada’s public drug plans is highlighted by the ...

Read more →

Onpattro (patisiran) now reimbursed in Canada for the treatment of hereditary transthyretin mediated amyloidosis

28 September 2021 - Onpattro is the only treatment that has demonstrated improvement in both polyneuropathy and quality of life ...

Read more →

Manitoba family calling for province to cover life-changing drug

26 September 2021 - A new drug called Trikafta could be a life-changing treatment option for people living with cystic ...

Read more →

Ontario providing access to life changing treatment for cystic fibrosis patients

24 September 2021 - Ontario is now providing coverage for Trikafta, the latest and most effective treatment option for cystic fibrosis ...

Read more →

Canada should negotiate a fairer share of drug R&D costs

23 September 2021 - Instead of relying on price regulation, Canada should engage in negotiations about drug pricing. ...

Read more →

Vertex announces letter of intent with pan-Canadian Pharmaceutical Alliance for public reimbursement of CFTR modulators Extended to Include Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor)

17 September 2021 - Vertex Pharmaceuticals today announced that it has signed a letter of intent with the pan-Canadian Pharmaceutical ...

Read more →